1. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
- Author
-
Botta, Gregory, Abdelrahim, Maen, Drengler, Ronald, Aushev, Vasily, Esmail, Abdullah, Laliotis, George, Brewer, Chris, George, Giby, Abbate, Steven, Chandana, Sreenivasa, Tejani, Mohamedtaki, Malla, Midhun, Bansal, Dhruv, Rivero-Hinojosa, Samuel, Spickard, Erik, McCormick, Nicole, Cecchini, Michael, Lacy, Jill, Fei, Naomi, Kasi, Pashtoon, Kasi, Anup, Dayyani, Farshid, Hanna, Diana, Sharma, Shruti, Malhotra, Meenakshi, Aleshin, Alexey, Liu, Minetta, and Jurdi, Adham
- Subjects
KRAS ,ctDNA ,molecular residual disease ,pancreatic adenocarcinoma ,Humans ,Circulating Tumor DNA ,Male ,Pancreatic Neoplasms ,Female ,Aged ,Middle Aged ,Retrospective Studies ,Carcinoma ,Pancreatic Ductal ,Aged ,80 and over ,Precision Medicine ,Adult ,Biomarkers ,Tumor ,Adenocarcinoma - Abstract
INTRODUCTION: Personalized and tumor-informed circulating tumor DNA (ctDNA) testing is feasible and allows for molecular residual disease (MRD) identification in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: In this retrospective analysis of commercial cases from multiple US institutions, personalized, tumor-informed, whole-exome sequenced, and germline-controlled ctDNA levels were quantified and analyzed in patients with PDAC. Plasma samples (n = 1329) from 298 clinically validated patients were collected at diagnosis, perioperatively (MRD-window; within 2-12 weeks after surgery, before therapy), and during surveillance (>12 weeks post-surgery if no ACT or starting 4 weeks post-ACT) from November 2019 to March 2023. RESULTS: Of the initially diagnosed patients with stages I-III PDAC who went for resection, the median follow-up time from surgery was 13 months (range 0.1-214). Positive ctDNA detection rates were 29% (29/100) and 29.6% (45/152) during the MRD and surveillance windows, respectively. Positive ctDNA detection was significantly associated with shorter DFS within the MRD window (median DFS of 6.37 months for ctDNA-positive vs 33.31 months for ctDNA-negative patients; HR: 5.45, P
- Published
- 2024